English
Spanish
Italian
French
Greek
Portuguese
Japanese
Danish
Dutch
Finnish
Croatian
Estonian
Filipino
Czech
Korean
Slovenian
Chinese (Simplified)
Chinese (Traditional)
Somali
Hebrew
Polish
Hindi
Hungarian
Slovak
Norwegian
Swedish
Persian
Romanian
Punjabi
Arabic
Ukrainian
Russian
Bulgarian
Indonesian
Bosnian
Afrikaans
Armenian
AlbanianTwo congressional committees recently released damning results of an 18-month investigation into the Food and Drug Administration’s approval of Biogen’s controversial Alzheimer’s drug, Aduhelm. The systems that enabled Biogen’s actions, however, went largely unscrutinized.
The report listed extensive and serious concerns about Aduhelm’s rollout, including “atypical” interactions and collaboration between the Useless FDA and Biogen; inappropriate use of the Useless FDA’s Accelerated Approval Program; initially approving the product for anyone with Alzheimer’s despite only testing it on patients in early and mild stages of the disease; and the company setting an “unjustifiably high price” for the drug. The report also noted that Biogen planned to spend billions of dollars on sales marketing for Aduhelm — more than twice its development costs for the product — with a specific strategy of targeting communities of color.
Click this link for the original source of this article.
Author: Daniel Eisenkraft Klein
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
